- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
| 0-1 month | 1-3 month | 3-12 month | 0-12 month (n=5) | 11-15 year(n=8) | |
| Dose | 0,5 mg/kg | ||||
| AUC0-infinity (ng*hour/ml) | 645 ± 249 | 580 ± 60 | |||
| Cmax (ng/ml) | 79,2 | 97,3 | |||
| Tmax (hour) | 2 (1-4,1) | 2,3 (2,1-2,9) | |||
| T½ (hour) | 10,5 | 8,1 | 4,5 | 5,82 | 2,13 |
| Cl (L/hour/kg) | 0,13 ± 0,06 | 0,21 ± 0,06 | 0,49 ± 0,17 | ||
Source: Product label Famotidine oral suspension FDA
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Gastro-esophageal reflux disease (GERD) |
|---|
|
| Peptic Ulcer Disease |
|---|
|
| Symptomatic treatment of hyperacidity in acid regurgitation and heartburn |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Agitation
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| H2-receptor antagonists | ||
|---|---|---|
| A02BA01 | ||
| A02BA02 | ||
| Proton pump inhibitors | ||
|---|---|---|
| A02BC05 | ||
| A02BC01 | ||
| A02BC02 | ||
| Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | ||
|---|---|---|
| A02BX13 | ||
| A02BX02 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Padagis, Product Label Famotidin oral suspension (NDC 0574-0147-04) , https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019527Origs032lbl.pdf
- Aurobindo Pharma B.V, SmPC Famotidine Sanias 10 mg (RVG 25579) 21-09-2023, www.geneesmiddelinformatiebank.nl
- Padagis, Product Label Famotidin oral suspension (NDC 0574-0147-04), https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019527Origs032lbl.pdf
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
